Novo Nordisk

Phase 3b trial data presented at ACC and published in NEJM highlights cardiovascular outcomes of oral semaglutide in patients with…

Growing patient awareness and emerging therapies drive obesity drug market expansion across the US, Europe, and Japan

The industry’s outlook remains uncertain as it navigates complex economic and political dynamics, reveals GlobalData

The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death from chronic kidney…

While mega-cap companies dominate the GLP-1R market and are expected to maintain their stronghold in 2030, three smaller biotechs…

Oral GLP-1 receptor drugs emerge as the next frontier in obesity treatment, with key players racing for first approval amidst…

The move taps into surging demand for appetite-suppressing GLP-1 agonists, set against ongoing shortages of newer weight-loss…

The market for oral GLP-1RAs is expanding, and Rybelsus’ latest results showed its benefits in reducing the risk in cardiovascular…

2024 top biotech and pharma employers survey by Science magazine identifies leading companies in the industry

Evotec to receive funding and potential milestone payments as Novo Nordisk explores stem cell-based therapies in diabetes and…